Immunotherapy with ligands of natural killer T cells

Michael T. Wilson, Avneesh K. Singh, Luc Van Kaer

Research output: Contribution to journalReview articlepeer-review

Abstract

Natural killer T (NKT) cells are innate lymphocytes that share receptor structures and functions with conventional T cells and natural killer cells. NKT cells are specific for glycolipid antigens bound by the major histocompatibility complex class I-like protein CD1d. One striking property of NKT cells is their capacity to rapidly produce large amounts of cytokines in response to T-cell receptor engagement, suggesting that activated NKT cells can modulate adaptive immune responses. Recent pre-clinical studies have revealed significant efficacy of NKT-cell ligands such as the glycolipid α-galactosylceramide for treatment of metastatic cancers and infections, and for prevention of autoimmune diseases. These findings suggest that appropriate stimulation of NKT cells could be exploited for prevention or treatment of human diseases.

Original languageEnglish (US)
Pages (from-to)225-231
Number of pages7
JournalTrends in Molecular Medicine
Volume8
Issue number5
DOIs
StatePublished - 2002
Externally publishedYes

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology

Fingerprint Dive into the research topics of 'Immunotherapy with ligands of natural killer T cells'. Together they form a unique fingerprint.

Cite this